Breast cancer Cancer Malignant neoplasm of breast
Conditions
Interventions
This is a prospective, observational, multicentre, longitudinal cohort study. This will be a national collaborative research study delivered in collaboration with the Association of Breast Surgery (AB
Sponsors
Leeds Teaching Hospitals NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Female or male patients more than 18 years old 2. Treated for previous unilateral or bilateral breast cancer (invasive cancer including all histological subtypes as well as ductal carcinoma in situ) with curative intent 3. No previous evidence of distant metastatic disease 4. Recently (within the last 6 months) diagnosed with new ipsilateral locoregional recurrence (biopsy-proven invasive cancer including all histological subtypes or ductal carcinoma in situ) +/- distant metastasis 5. Able to provide written informed consent 6. A minimum of 3 months interval between the resection surgery for the original cancer and the diagnosis of locoregional recurrence. There will be no maximum interval time period
Exclusion criteria
Exclusion criteria: 1. Patients where the new breast cancer diagnosis is in the contralateral breast 2. For patients who present with new bilateral breast cancer, the side with no previous cancer will be excluded 3. Patients diagnosed with distant metastatic disease with no evidence of locoregional recurrence 4. Patients diagnosed with angiosarcoma 5. Patients with previous history of non-breast cancer treatment that was non-curative in intent 6. Patients who have had previous ipsilateral surgery for atypia, benign conditions, or phyllodes tumour and other breast sarcomas 7. Patients under 18 years old 8. Patients lacking the capacity to provide written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival following locoregional recurrence resection measured using patient records at 3 and 5 years follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Progression-free survival in patients who present with breast cancer locoregional recurrence with distant metastasis (3 and 5 years follow up). 2. Overall survival in patients diagnosed with breast cancer locoregional recurrence +/- distant metastasis at presentation (3 and 5 years follow up) | — |
Countries
England, Northern Ireland, Scotland, United Kingdom, Wales
Outcome results
None listed